The regulation of neuropeptide expression in rat anterior pituitary following chronic manipulation of estrogen status: a comparison between substance P, neuropeptide Y, neurotensin, and vasoactive intestinal peptide.

O'Halloran DJ, Jones PM, Ghatei MA, Domin J, Bloom SR

Endocrinology1 Sept 1990Cited by 42 (Europe PMC)

PMID1696887DOI10.1210/endo-127-3-1463PepBankPUB-01696887

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Other
In rats, surgical ovariectomy decreased pituitary VIP immunoreactivity versus control.
In plain wordsIn rats, removing the ovaries lowered the body's own VIP in the pituitary gland compared with control rats.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePituitary VIP content after ovariectomy
Study
ratn: not reported in source
anterior pituitary
Comparator
Control
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
VIP immunoreactivity
201.2 fmol/gland
ovariectomy
VIP immunoreactivity
285.4 fmol/gland
control
Source sentences
Summary
while vasoactive intestinal peptide IR showed a fall (201.2 +/- 18.8 vs. 285.4 +/- 25.9, P less than 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of estrogen manipulation on pituitary and hypothalamic expression of these four peptides by specific RIAs and cDNA probe analysis.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0169688701
02AnimalEndogenous levelAnimal study (in vivo)Other
In ovariectomized rats, estrogen replacement or high dose estrogen reversed the fall in pituitary VIP, among other peptide changes.
In plain wordsIn rats without ovaries, estrogen brought the body's own pituitary VIP back toward its earlier level.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePituitary VIP content with estrogen replacement or high dose estrogen
Study
ratn: not reported in source
anterior pituitary
Comparator
Ovariectomized rats
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
These patterns were reversed with estrogen replacement or high dose estrogen treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of estrogen manipulation on pituitary and hypothalamic expression of these four peptides by specific RIAs and cDNA probe analysis.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0169688702
03AnimalEndogenous levelAnimal study (in vivo)Other
In rats, changes in pituitary VIP content were accompanied by parallel changes in VIP mRNA.
In plain wordsIn rats, changes in the body's own pituitary VIP went together with changes in its mRNA.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
MixedPituitary VIP mRNA
Study
ratn: not reported in source
anterior pituitary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Changes in peptide content were accompanied by parallel changes in the mRNA for each peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of estrogen manipulation on pituitary and hypothalamic expression of these four peptides by specific RIAs and cDNA probe analysis.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0169688703
04AnimalEndogenous levelAnimal study (in vivo)Other
In rats, tamoxifen decreased pituitary VIP immunoreactivity to below the assay detection limit.
In plain wordsIn rats, tamoxifen lowered the body's own pituitary VIP below the level the test could detect.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePituitary VIP content after tamoxifen
Study
ratn: not reported in source
anterior pituitary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
while vasoactive intestinal peptide IR content decreased to below the assay detection limit.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of estrogen manipulation on pituitary and hypothalamic expression of these four peptides by specific RIAs and cDNA probe analysis.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0169688704
05AnimalEndogenous levelAnimal study (in vivo)Other
In rats, hypothalamic expression of the peptides, including VIP, did not change with any of the treatments.
In plain wordsIn rats, the body's own VIP in the hypothalamus did not change with any treatment.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeHypothalamic VIP expression
Study
ratn: not reported in source
hypothalamus
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Hypothalamic expression of these peptides did not change with any of the treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of estrogen manipulation on pituitary and hypothalamic expression of these four peptides by specific RIAs and cDNA probe analysis.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0169688705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.